8:30 am Check-In & Coffee

9:20 am Chair’s Opening Remarks

Optimizing Purification Strategies to Tackle Free Payload Impurities & Decrease Unit Operations

9:30 am Optimizing the Post-Conjugation TFF Process to Improve Impurity Clearance & Increase Process Robustness

  • Joshua Hunter Director - Conjugation Process Development, Pfizer

Synopsis

  • Developing robust ADC manufacturing process
  • Optimizing removal of drug-linker related impurities
  • Improving the performance of TFF processes to reduce processing time

10:00 am Developing a Novel Non-Chromatographic Purification for ADCs: Moving Beyond UF/DF

Synopsis

  • Surveying alternative purification strategies
  • Developing novel purification of CL2A-SN38 impurities
  • Evaluating characterization strategies for new purification technologies

10:30 am Morning Break & Speed Networking

Synopsis

This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of experts in toxicology eager to discuss shared challenges, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters.

To submit a poster, please contact info@hansonwade.com

Considering Process Characterization to Ensure the Robustness of Your Process Development to Reduce Risk of Batch Failure

11:30 am Process and Analytical Development of Drug-Fc Conjugates (DFCs)

  • Robert Hughes Senior Director - Pharmaceutical Sciences, Cidara Therapeutics Inc.

Synopsis

  • Evaluate Cidara Therapeutics’ DFCs developments to address serious diseases
  • Compare and expand upon the strengths of small molecules and antibody therapeutics using the uniquely tunable DFCs platform
  • Address the unique challenges associated with each DFCs product development, considering disease area, dose regimen, and properties

12:00 pm Evaluating the Correct Timings to Introduce Process Characterization to Assess the Robustness of Your ADC Process Development

Synopsis

  • Reviewing considerations in FIH and commercial process development and their impact in process characterization strategy
  • Deciding when to start your process characterization experiments dependent on your timelines
  • Discussing advances in analytical techniques for the characterization of a manufacturing process

12:30 pm Networking Lunch

Handling Deviations & Safety Challenges When Manufacturing ADCs Ensure Employee Wellbeing

1:30 pm Panel Discussion – Accelerating Process Development Scale-Up to Manufacturing for ADCs

Synopsis

  • Addressing the largest challenges posed to both process development scientists and manufacturers when accelerating scale-up processes
  • Considering potential solutions for a more streamlined scale-up process through     inter-departmental collaboration
  • Delving into how service providers can aid with scale-up of ADC process development

2:15 pm Afternoon Break

3:00 pm Creating a Corrective & Preventative Action Framework for Overcoming Deviation Challenges in ADC Manufacturing

Synopsis

  • Identifying and investigating deviations, and implementing corrective actions.
  • Preventive actions, documentation, and ongoing monitoring.
  • Ensuring compliance with regulatory standards and guidelines.

Considering Process Characterization to Ensure the Robustness of Your Process Development to Reduce Risk of Batch Failure

3:30 pm Developing a Cell Based Assay for Evaluating the Potency of Engineered Monoclonal Antibodies to Improve Timings & Gain Regulatory Approval

Synopsis

  • Discussing ways to improve timelines for cell-based assays with minimal costs
  • Considering alternatives to cell-based assays and ion exchange chromatography to achieve regulatory approval
  • Controlling antibody oscillation frequency through changes in cell culture

4:00 pm Chair’s Closing Remarks

4:10 pm End of Conference Day Two